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ABSTRACT

ARTICLE HISTORY

Background: Developing, monitoring, and reporting of fidelity are
essential and integral components to the design of randomised con
trolled trials (RCTs) in stroke and aphasia. Treatment fidelity refers to the
degree to which an intervention is delivered as intended and is directly
related to the quality of the evidence generated by RCTs. Clear doc
umentation of treatment fidelity in trials assists in the evaluation of the
clinical implications of potential benefits attributed to the intervention.
Consideration of the implementation requirements of a research-based
intervention as intended in a clinical context is necessary to achieve
similar outcomes for a clinical population. Despite this, treatment
fidelity is rarely reported in RCTs of aphasia intervention.
Aim: To describe fidelity strategies and develop core recommenda
tions for developing, monitoring, and reporting of fidelity in apha
sia intervention RCTs.
Scope: Relevant conceptual frameworks were considered. The
Behaviour Change Consortium comprehensive framework of fidelity
was adopted. It includes five areas: study design, training providers,
delivery of treatment, treatment receipt, and treatment enactment. We
explored fidelity in RCTs with a range of complex aphasia interventions
(e.g., ASK, Big CACTUS, COMPARE, FCET2EC, POLAR, SUPERB, and
VERSE) and described how different trial design factors (e.g., phase of
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trial, explanatory vs. pragmatic, number and location of sites, and
number and type of treatment providers) influenced the fidelity stra
tegies chosen. Strategies were mapped onto the five areas of the
fidelity framework with a detailed exploration of how fidelity criteria
were developed, measured, and monitored throughout each trial. This
information was synthesised into a set of core recommendations to
guide aphasia researchers towards the adequate measurement, cap
ture, and reporting of fidelity within future aphasia intervention
studies.
Conclusions/Recommendations: Treatment fidelity should be
a core consideration in planning an intervention trial, a concept
that goes beyond treatment adherence alone. A range of strategies
should be selected depending on the phase and design of the trial
being undertaken and appropriate investment of time and costs
should be considered.

This paper is part of a special series of papers in Aphasiology on Methodological Issues in
Aphasia Trials. The series comprises tutorial-type papers with core recommendations for
aphasia intervention studies and RCTs. The series is guest edited by Professor Katerina
Hilari, Dr Caterina Breitenstein, Dr Erin Godecke, Dr Helen Kelly, and Professor Miranda
Rose on behalf of the Trials for Aphasia Panel of the Collaboration of Aphasia Trialists
https://www.aphasiatrials.org/

Introduction
Treatment fidelity refers to the “methodological strategies used to monitor and
enhance the reliability and validity of behavioural interventions” (Bellg et al., 2004,
p. 443) and is becoming increasingly recognised as an important quality marker for clinical
trials (Bellg et al., 2004; Mowbray et al., 2003; Walker et al., 2017). Reporting fidelity can
assist researchers to identify the essential elements that help make a treatment work
(Carroll et al., 2007). Demonstrating fidelity is an important component in determining an
intervention’s replicability, efficacy, and effectiveness.
Fidelity is a multifaceted concept that has evolved over time (Bellg et al., 2004; Carroll
et al., 2007). Early definitions of fidelity focused on treatment delivery, which Moncher and
Prinz (1991) separated into issues related to treatment integrity and differentiation.
Treatment integrity relates to whether a treatment is carried out as intended with adequate
levels of adherence and competence (Perepletchikova et al., 2007); treatment differentiation
refers to whether one treatment differs from another (Kazdin, 1986). Treatment integrity and,
in particular, adherence to the protocol have historically been considered as the main factors
demonstrating sufficient fidelity (Carroll et al., 2007; Mowbray et al., 2003; Orwin, 2000;
Walker et al., 2017). Adherence to a treatment protocol is the minimum standard for fidelity,
referring to the degree to which providers deliver the intervention as specified in the manual
(Carroll et al., 2007; Perepletchikova et al., 2007). Treatment receipt and enactment were later
added to expand further the definition of fidelity (Lichstein et al., 1994). Treatment receipt
refers to a participant’s ability to understand and perform the treatment skills (demonstrated,
e.g., in pre-post tests, homework, and self-practice logs), while treatment enactment refers to
a participant’s ability to independently use learnt treatment skills in relevant daily-life
settings (demonstrated, e.g., in direct observation, self-report, or follow-up discussion).
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The Treatment Fidelity Workgroup of the National Institutes of Health Behaviour
Change Consortium (BCC) reviewed existing definitions and treatment fidelity strategies
and developed recommendations for consistent reporting (Bellg et al., 2004). The group
identified two other areas related to fidelity: study design, which refers to methods that
ensure a study can adequately test the hypotheses under investigation; and training
providers, which are methods that ensure treatment providers are satisfactorily trained
to deliver the treatment. These five areas of fidelity (study design, training providers,
delivery of treatment, receipt of treatment, and enactment of treatment skills) will be used
and referred to throughout this manuscript. The BCC workgroup has further described
and refined methods for assessing, monitoring, and enhancing treatment fidelity for all
five areas (Borelli et al., 2005; Borrelli, 2011).
Monitoring fidelity is important for maintaining the internal and external validity of a study
(Moncher & Prinz, 1991). Importantly, in terms of internal validity, fidelity results may help
explain negative, null, or ambiguous findings (Hohmann & Shear, 2002; Resnick et al., 2005). In
the absence of fidelity, it is difficult to determine whether a null trial was driven by poor
adherence to a specified protocol or ineffectiveness of the treatment itself (Carroll et al., 2007;
Perepletchikova et al., 2007). Moreover, monitoring fidelity can help decrease deviations from
the treatment protocol, including any instances of therapist or programme drift (Mowbray
et al., 2003). Measuring drift is important to show provider skills are maintained consistently
across the trial with no change or decay from the beginning to the end of treatment.
In terms of external validity, the benefits of considering and evaluating fidelity include an
opportunity to identify or confirm the active ingredients of treatment that contribute to
efficacy findings (Bellg et al., 2004; Moncher & Prinz, 1991). Active ingredients refer to
intervention-specific components serving as key levers of change (Abry et al., 2015).
Fidelity monitoring enables researchers to replicate the findings of the study and make
comparisons across other similar studies, which is important for maintaining external validity.
Finally, the lack of standardisation of provider training and monitoring of adherence to
treatment protocols will impede study replication (Mowbray et al., 2003; Resnick et al., 2005).
When designing a fidelity evaluation, it is essential to consider the phase and purpose
of the trial. In 2000, The Medical Research Council (Campbell et al., 2000) described
a series of phases in the evaluation of complex interventions ranging from pre-clinical
(i.e., laboratory animal studies) and early studies on the safety and modelling components
(phase I) to preliminary evaluation needed to identify key components and test the
feasibility of an intervention (phase II), to comparing the intervention to an appropriate
alternative (phase III) and, lastly, testing whether an intervention works in everyday
practice and gains are maintained in the long term (phase IV).
The purpose of the trial—explanatory or pragmatic—should also be considered. An
explanatory trial determines the efficacy of an intervention in tightly controlled conditions
to establish whether the intervention “can” work under ideal conditions (Zwarenstein et al.,
2008). In contrast, pragmatic trials determine the effectiveness of an intervention if it were
implemented in routine clinical practice, by asking “does it work in the ‘real world’?”; the latter
can often result in a more flexible application of the intervention with a more inclusive sample
and multiple providers as well as individual adjustments of the therapeutic approach
(Zwarenstein et al., 2008). Where a trial sits on the explanatory–pragmatic continuum can
be determined using the PRagmatic Explanatory Continuum Indicator Summary 2 (PRECIS-2;
Loudon et al., 2015).
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The recommended practices for ensuring and monitoring fidelity proposed by the BCC
are more applicable to explanatory than to pragmatic trial designs. Detailed recommen
dations for ensuring fidelity in pragmatic trials are yet to be published. However, as more
pragmatic trials focus on interventions closer in nature to routine care evaluation, fidelity
frameworks from the implementation literature, such as the Conceptual Framework for
Implementation Fidelity (Carroll et al., 2007), have been utilised (Masterson-Algar et al.,
2014; J. Palmer et al., 2019). In pragmatic, routine care trials, it is essential that strategies to
enhance fidelity, such as provider training and relaying fidelity evaluation findings back to
providers, do not go beyond that which can be delivered in routine clinical practice
outside of a trial (Miller & Rollnick, 2014). Implementation fidelity models place greater
focus on measuring the fidelity, with strategies to ensure fidelity needing to be built into
the intervention itself, rather than relying on external trial processes (Carroll et al., 2007).
From development to reporting, fidelity should be an integral component of interven
tion trial design (Walker et al., 2017). Despite this, treatment fidelity procedures were not
included within international clinical trial reporting guidelines such as the Consolidated
Standards of Reporting Trials (CONSORT 2010, Eldridge et al., 2016) until the Template for
Intervention Description and Replication (TIDieR) extension (Hoffman et al., 2014).
In stroke rehabilitation and aphasia studies, fidelity is rarely reported. For example, in
published stroke rehabilitation trials during 2015, fidelity was reported for fewer than 10%
of trials, with most studies addressing a single aspect of fidelity such as adherence (Walker
et al., 2017). In post-stroke aphasia intervention studies, the measurement and reporting
of fidelity is still in its infancy. A review of 149 studies published between 2002 and 2011
revealed that only 14% of studies reported on fidelity (Hinckley & Douglas, 2013).
Systematic reviews of specific interventions for people with post-stroke aphasia have
highlighted that fewer than 27% of studies reported fidelity (Cherney et al., 2008, 2013;
Faroqi-Shah et al., 2010; Purdy et al., 2019; Rose et al., 2013; Simmons-Mackie et al., 2010,
2016). More recently, 21% of aphasia RCTs from 2012 to 2017 explicitly reported fidelity
(Brogan et al., 2019). In these 42 aphasia RCTs, only one study addressed all five fidelity
areas (Marshall et al., 2016). Approximately half the studies addressed either training
providers or delivery of treatment (Brogan et al., 2019).
In designing a fidelity evaluation plan, criteria for fidelity assessment need to be clearly
identified and specified a priori (Mowbray et al., 2003). This process involves specifying
the active ingredients of a treatment and defining “standard operating procedures” to
ensure the treatment is delivered as planned (Moncher & Prinz, 1991). A fidelity protocol
should include the training and ongoing supervision of providers and development of
a treatment manual to help minimise provider or therapist drift (Hildebrand et al., 2012;
Moncher & Prinz, 1991). Further criteria to measure fidelity should also be established;
these criteria may be structural (e.g., the planned frequency and intensity of contact),
which require less subjective judgements, or process-related (e.g., staff–client or client–
client interactions), which are more subjective and often based on observation (Mowbray
et al., 2003). Direct observation by trained and reliable raters of treatment sessions using
a prescribed list of criteria (or behaviours) is considered the gold standard of fidelity
measurement (Hart, 2009; Kaderavek & Justice, 2010; Markowitz et al., 2000; Moncher &
Prinz, 1991; Mowbray et al., 2003). In their review of aphasia studies, Hinckley and Douglas
(2013) report that about half of the studies (13/21) checked adherence by having raters
review 10–20% of videotapes of sessions for the presence of target behaviours.

APHASIOLOGY

5

The TIDieR extension to the CONSORT 2010 statement is recommended to encourage
more transparent reporting of treatments. Not only does this template advocate for
a complete and detailed description of an intervention (e.g., materials, procedure, how,
where, when, and how much), but fidelity is also a core part. Two items (11 and 12)
explicitly refer to planned and actual fidelity strategies undertaken in an intervention trial.
These items have since been matched to the BCC’s five areas of fidelity (Item 11: study
design, training providers, delivery of treatment; Item 12: receipt of treatment, enactment
of treatment skills). The actual outcome of planned fidelity strategies is less commonly
reported in aphasia intervention trials (Brogan et al., 2019).
While fidelity monitoring and reporting may not have been historically common
practice in aphasiology, more recently, the field has become increasingly aware of the
importance of the development, implementation, evaluation, and reporting of fidelity
strategies. This paper aims to provide examples of how fidelity was addressed across
recent aphasia RCTs of different types and scales and build on existing frameworks to
develop core recommendations for developing, monitoring, and reporting of fidelity.

Scope/Methods
To explore the measurement of fidelity and strategies used, seven RCTs for people with
post-stroke aphasia from four countries (Australia, Germany, UK, USA) were examined.
Considering the latest review of fidelity in aphasia RCTs covering trials up to 2017 (Brogan
et al., 2019), we specifically included RCTs that were published or ongoing (with
a published protocol) in the period from 2017 to the present. The trials needed to have
a detailed description of planned fidelity as a minimum to be used as exemplars of current
practice in fidelity monitoring and reporting. The selected studies comprised four expla
natory (phases II and III) and three pragmatic (phases III and IV) trials. Explanatory trials
included one feasibility and three definitive trials. The feasibility trial was of a peerbefriending intervention for people with aphasia and low levels of distress when dis
charged from hospital and active interventions cease (typically <6 months post-stroke)
(SUPERB, Hilari et al., 2019). The three definitive trials were intensive aphasia therapy in
the very early weeks post-stroke (VERSE, Godecke et al., 2021); multi-modal and con
straint-induced aphasia therapy in the chronic phase (>6 months) post-stroke (COMPARE,
Rose, Copland et al., 2019); and aphasia language therapy more than 12-months poststroke (POLAR, Spell et al., 2020). Pragmatic trials included a psychosocial intervention to
prevent depression in the early months post-stroke (ASK, Worrall et al., 2016), selfmanaged computerised speech and language therapy more than 4-months post-stroke
(Big CACTUS, Palmer et al., 2020; R.2019), and intensive “agreed best practise” aphasia
therapy starting at least 6-months post-stroke (FCET2EC, Breitenstein et al., 2017). Further
information about trial design, sample size, and intervention characteristics is provided for
each trial in Table 1.
To select studies for inclusion and describe the fidelity strategies of each trial, we considered
peer-reviewed academic publications, information in the public domain including trial proto
cols, fidelity monitoring plans, and treatment manuals, and sought additional information
from study authors. First, studies needed to have provided information on fidelity in either
peer-reviewed publications and/or other forums in the public domain as above. Then, the
study authors of each trial rated their own study and whether they had “met”, “partially met”,

Phase II, explanatory,
multicentre, openlabel, blinded
endpoint, crossover
RCT

120 (target)

2 university clinics/
community

≥12 months

Actual/target
sample size
Number of sites/
setting

Aphasia phase

POLAR
Spell et al. (2020)

RCT phase and
type*

Study reports

>6 months

<6 months and
study
participation
continued to
12-months
post-onset

<6 months

Urban
20 clusters (health 5 Hospitals +
community
regions)
linked
facilities and
community
University
services; 13
clinics
GP practices

17 acute care hospital; 45
19 inpatient and
subacute hospital and home
outpatient
centres; day-care
treatment
facilities;
hospitals;
independent
SLTs
<15 days
≥6 months

>4 months

(Continued)

21 community sites

COMPARE
ASK
SUPERB
VERSE
FCET2EC
Big CACTUS
Rose et al.
Worrall et al.
Hilari et al.
Godecke et al. (2016); Godecke Baumgaertner et al. Palmer et al. (2020)
(2019); Rose
(2016);
(2019); Hilari
et al. (2021); under
(2013);
Harrison (2019)
et al. (2019)
Carragher et al.
et al. (2021);
submission)
Breitenstein et al.
(2019)
Behn et al.
(2017)
(2021)
Phase III,
Phase III,
Phase II,
Phase III, explanatory,
Phase III/IV,
Phase IV, pragmatic,
explanatory,
pragmatic,
explanatory,
multicentre, open-label,
pragmatic
superiority, multicentre,
multicentre,
superiority
feasibility,
three arm, blinded
multicentre,
three arm, single-blind,
open-label,
multicentre,
multicentre,
endpoint, parallel group RCT
open-label,
parallel group RCT
blinded
cluster, doublesingle-blind
blinded end
endpoint,
blind, parallel
(intervention
point, parallel
parallel
group RCT
arm)/
group RCT
group RCT
double-blind
(control arm),
parallel
group
RCT
216 (actual)
344 (target)
56 (actual)
246 (actual)
158 (actual)
278 (actual)

Table 1. Study and intervention characteristics of aphasia intervention trials.
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Speech and language
therapist

Provider

Speech and
language
therapist

3 arms:
usual care
CIAT Plus
M-MAT

COMPARE

SUPERB

VERSE

FCET2EC

2 arms: ASK
2 arms: usual
3 arms: usual Care + 15–
2 arms: intensive
psychosocial
care + peer20 hours of standard wardagreed best
intervention vs.
befriending
based aphasia therapy vs.
practice + selfattention
vs. usual care
usual care + 15–20 hours
managed
control
control
prescribed therapy
(computerised)
(secondary
(targeting spoken output)
language
stroke
vs. usual care control
exercises vs.
prevention
waiting list
information)
control
Speech and
Person with
Speech and language therapist Speech and
language
aphasia
language
therapist
therapist

ASK

Self-managed with support
from speech and language
therapist and volunteer/
assistant

3 arms: usual care + selfmanaged computerised
speech and language
therapy vs. usual care +
attention control (puzzle
books and phone calls) vs.
usual care control

Big CACTUS

See glossary of terms
Note. POLAR = Predicting Outcomes of Language Rehabilitation; COMPARE = Constraint-induced Or Multi-modal Personalised Aphasia Rehabilitation; ASK = Action Success
Knowledge; SUPERB = SUpporting wellbeing through PEeR Befriending; VERSE = Very Early Rehabilitation in SpEech; FCET2EC = From Controlled Experimental Trial to Everyday
Communication; CACTUS = Clinical and cost-effectiveness of Aphasia Computer Treatment vs. Usual Stimulation or attention control long-term post-stroke; CIAT-Plus
= Constraint-Induced Aphasia Therapy Plus; M-MAT = Multi-modality Aphasia Therapy.

*

2 arms: semantically
focused therapy using
3 approaches vs.
phonologicallyfocused
therapy using 3
approaches

POLAR

Intervention and
control arms

Table 1. (Continued).
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or “not met” the fidelity practice requirements according to treatment fidelity strategies within
the five areas of fidelity proposed by Bellg et al. (2004): study design, training providers,
delivery of treatment, receipt of treatment, and enactment of treatment skills. The study
authors’ ratings were reviewed for inclusion of each study in this review by the first and last
authors of the present paper to ensure fidelity strategies were used across at least four of the
five areas.
Each trial was then rated by two different raters, who were experienced aphasia trialists
and co-authors of this paper but who were independent of the RCT study they were
rating. Raters reviewed the published documents and rated whether fidelity strategies
were met in each RCT. The independent raters were not aware of the ratings provided by
the study authors. Planned (if ongoing) and actual (if completed) fidelity strategies were
rated. Each rater was required to independently review the published documents for
fidelity strategies relevant to the specific area and make a judgement as to whether the
trial had “met”, “partially met”, or “not met” the requirements. Resources to rate fidelity,
that is, relevant papers (Bellg et al., 2004; Borelli et al., 2005; Borrelli, 2011) were given to
the raters; but no training was provided.
To examine the inter-rater reliability of the independent raters, Gwet’s AC1 was used (Gwet,
2002, 2014). Unlike Cohen’s Kappa, Gwet’s AC1 can be calculated even when one rater’s scores
are a constant/do not vary; Gwet’s AC1 is less susceptible to skew due to prevalence
(Wongpakaran et al., 2013). A reliability coefficient of 0.81–1.00 is considered very good;
0.61–0.80, good; 0.41–0.60, moderate; 0.21–0.40, fair; and below 0.20, poor (Gwet, 2014).
Statistical analyses were carried out using STATA version 15.
As disagreements in some of the ratings emerged, definitions of fidelity areas and
fidelity strategies were discussed among the raters assigned to the same study to
explore differences. Raters then met to reach an agreement on the rating by consensus.
Based on the review of published documents for each trial, fidelity ratings, and com
ments on the seven trials by authors and raters, key fidelity strategies used across trials
were described. Through a review of these strategies (planned or actual), the author
team then agreed on a set of recommendations for which areas of fidelity should be
considered essential or desirable across trial phases and the explanatory to pragmatic
continuum.

Results
For inter-rater reliability of fidelity ratings, there was a fair to very good level of agreement
between raters. There was fair agreement for the ASK (Gwets AC1 = 0.33 [95% CI, −0.10,
0.75], p = 0.12) and VERSE (Gwets AC1 = 0.37 [95% CI, −0.04,0.79], p = 0.07) trials. There
was moderate agreement for COMPARE (Gwets AC1 = 0.42 [95% CI, 0.20, 0.82], p = 0.04),
Big CACTUS (Gwets AC1 = 0.51 [95% CI, 0.13, 0.89], p = 0.01), and SUPERB trial (Gwets
AC1 = 0.57 [95% CI 0.20, 0.95], p = 0.005). There was very good agreement for the POLAR
(Gwets AC1 = 0.84 [95% CI, 0.60, 1.00] p < 0.001) and FCET2EC (Gwets AC1 = 0.86 [95% CI,
0.63, 1.00], p < 0.001) trials. Overall, across all raters and trials, there was 63% agreement
(ranging from 43.8% to 87.5% agreement). However, when the categories “partially met”
and “met” were collapsed into one, the agreement increased to 84% (ranging from 75%
to 100%).
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Table 2 shows the final ratings agreed for each area of fidelity and the extent to which
each component was “met”, “partially met”, or “not met”. Training providers and delivery
of treatment were addressed more completely than other areas of fidelity. Treatment
receipt and enactment were addressed less well.
There were subtle and distinct differences across all trials as to the strategies employed
for each fidelity area according to the type and phase of the trial. Below is a summary of
key strategies used across the seven trials (Table 3). It should be noted that fidelity
strategies were either planned for ongoing trials at the time of writing this manuscript
(i.e., POLAR, ASK, and COMPARE) or actual reported for completed trials (i.e., SUPERB,
VERSE, FCET2EC, and Big CACTUS). It is noted that as Big CACTUS was a pragmatic trial,
which aimed to monitor rather than ensure fidelity, many areas are marked as partially
met, given the focus of the Bellg framework on ensuring fidelity. Instances of extended
practice are identified to highlight examples where a trial went beyond the expectations
of fidelity monitoring detailed by Bellg et al. (2004).

Strategies to address study design
In planning a treatment trial, the theory underpinning the treatment should be described
and essential components or active ingredients identified. While this was completed
across all trials, some trials did this more explicitly in publications focused on treatment
fidelity (e.g., ASK, SUPERB, and VERSE). A number of trials also did pilot studies to explore
the active ingredients in depth (e.g., ASK, Big CACTUS, COMPARE, SUPERB, and VERSE).
To ensure fidelity, key issues to consider when planning a study are dose within and
across conditions and strategies to address implementation setbacks (Bellg et al., 2004).
To ensure and monitor the same treatment dose within conditions, all trials planned to or
recorded the length and number of all contacts. For trials with an independent practice
component in the intervention arm, information was planned or recorded on the number
and length of practice sessions (e.g., Big CACTUS, COMPARE, and FCET2EC). An example of
extended practice in monitoring dose was in the VERSE trial, where participants in all trial
arms had a proportion of treatment sessions videorecorded and independently assessed
for overall treatment protocol adherence.
The data recorded on length and number of contacts were also used to ensure equiva
lence of dose across conditions. Other strategies were also employed, such as recording any
speech and language therapy and other services received by participants including those in
the control arm (e.g., ASK, Big CACTUS, COMPARE, FCET2EC, SUPERB, and VERSE); and having
participants document therapy activity using a study-specific diary in the control arm or have
providers keep a daily therapy log for those in the intervention arm (e.g., COMPARE and
FCET2EC). In some cases, ensuring the same treatment dose within and equivalence of dose
across conditions is not possible or desirable. For example, pragmatic trials in routine care,
where there may be variability in how much therapy provision is funded by healthcare
providers (e.g., FCET2EC) or for self-managed interventions where the aim is to increase the
dose of therapy in the intervention arm only (e.g., Big CACTUS, and VERSE).

Not met
Not met

Not met
Not met

Met
Not met
Not met

Met
Met
Met
Met

Met
Met
Met
Met
Met
Met
Met

Met
Met
Partially met
Met

Partially met
Partially met
Partially met

Met
Met
Met
Partially met

Met
Met
Partially met

ASK
Carragher et al.
(2019)

Planned fidelity

Partially met
Partially met

Partially met
Not met
Met

Met
Met
Met
Met

Met
Met
Partially met
Partially met

Met
Partially met
Partially met

COMPARE
Rose et al.
(2019)

Partially met
Partially met

Met
Met
Partially met

Met
Met
Met
Met

Met
Met
Met
Met

Met
Partially met
Met

SUPERB
Behn et al.
(2021)

Not met
Not met

Met
Partially met
Partially met

Met
Met
Met
Met

Partially met
Partially met
Met
Partially met

Met
Not met
Met

Partially met
Met

Met
Met
Met

Partially met
Met
Met
Met

Met
Met
Met
Met

Partially met*
Met
Partially met

FCET2EC
Breitenstein et al.
(2017)

Actual fidelity
VERSE
Godecke et al. (under
submission)

Met
Met

Partially met
Partially met
Partially met

Partially met
Partially met
Partially met
Partially met

Partially met
Partially met
Partially met
Partially met

Not met
Not met
Partially met

Big CACTUS
Palmer et al.
(2020);
Harrison
(2019)

* In FCET2EC, the same treatment dose across participants was not an option as it was an ethical requirement to provide the maximum amount of therapy funded by the individual’s health
insurance plan. For the first (and most relevant) follow-up assessment after three weeks though, dose was highly comparable across participants within the intervention condition (at least 80%
of the prespecified dose).
POLAR = Predicting Outcomes of Language Rehabilitation; COMPARE = Constraint-induced Or Multi-modal Personalised Aphasia Rehabilitation; ASK = Action Success Knowledge;
SUPERB = SUpporting wellbeing through PEeR Befriending; VERSE = Very Early Rehabilitation in SpEech; FCET2EC = From Controlled Experimental Trial 2 Everyday Communication;
CACTUS = Clinical and cost-effectiveness of Aphasia Computer Treatment vs. Usual Stimulation or attention control long-term post-stroke.

Treatment enactment
Ensure participant use of cognitive skills
Ensure participant use of behavioural skills

Receipt of treatment
Ensure participant comprehension
Ensure participant ability to use cognitive skills
Ensure participants ability to perform
behavioural skills

Training providers
Standardise training
Ensure provider skill acquisition
Minimise therapist drift
Accommodate provider differences
Delivery of treatment
Control for provider differences
Reduce differences within treatment
Ensure adherence to protocol
Minimise contamination between conditions

Study design
Ensure same treatment dose within conditions
Ensure equivalent dose across conditions
Plan for implementation setbacks

Fidelity report

POLAR
Spell et al.
d(2020)

Table 2. Description of fidelity strategies and number of strategies rated as met, partially met, or not met in each trial.
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Ensures treatment providers have been satisfactorily trained to deliver
intervention

Monitor and improve the delivery of the intervention so that that the protocol is
delivered as intended

Training
providers

Delivery of
treatment

Rationale
Study Design Ensures a study can adequately test its hypotheses in relation to underlying
theory and clinical processes

Table 3. Example strategies for each area of fidelity across recent aphasia RCTs.
Example strategies

●
●
●
●
●
●
●
●
●
●

●
●
●
●
●

●
●
●
●
●

●
●
●
●
●

●
●
●
●
●

(Continued)

homework sessions (in all trial arms)
Videorecorded sessions to independently assess for adherence
Study-specific record sheet or daily therapy logs
Supervision and training of providers
Train more providers than required
Allow additional time for recruitment of participants and intervention to manage
setbacks
Same or certified trainers with set qualifications and/or experience levels
Training material described
Standardised training
Length of training recorded
Videorecorded training and/or treatment sessions to independently assess pro
viders skills and competence
Feedback to providers
Knowledge quiz to providers at regular intervals
Regular provider face-to-face supervision, site visits, or telephone calls
Booster or refresher training or support
Predetermined acceptable level of protocol adherence for reported treatment
sessions
Daily therapy logs or visit records
Monitor information recorded by computer software
Standardisation of intervention elements to participants
Recording adverse events, complaints, problems, or protocol deviations
Videorecorded intervention sessions and independently assess for adherence
with fidelity checklist
Audio or videorecorded sessions
Qualitative participant interviews
Participant questionnaires of their experiences
Supervision and feedback to providers at regular intervals or when required
Standardised intervention manual and/or scripted intervention protocol
Providers deliver a single intervention
Providers do not liaise with other conditions or trial arm
Different intervention conditions occur in different locations
Close monitoring of intervention or services received by all trial arms
Study participants in control arm explicitly not aware of intervention (if feasible)

● Specified theory underpinning treatment and essential components identified.
● Record the length, number, and frequency of all contacts including practice and
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Treatment
Monitor and improve the ability of participants to perform the skills being taught in
enactment
real-life settings

Treatment
receipt

Rationale

●
●
●
●

●
Monitor and improve the ability of participants to understand the intervention and
perform the skills being taught in intervention sessions (behavioural and cognitive) ●
●
●

Table 3. (Continued).
Providers have skills or been trained to facilitate communication
Inclusion and exclusion criteria ensure participants have skills to participate
Incremental or stage structure to learning skills
Review of videotaped intervention sessions, daily therapy logs, or homework
exercises
Ratings of goal achievement
Monitoring functional tasks, e.g., conversation and group performance
Qualitative participant interviews
Opportunities to practice trained items/behaviours in functional communication
tasks, e.g., conversation and self-reported outcomes or behavioural measures

Example strategies
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To manage setbacks, trials described careful ongoing monitoring through supervision
and training (e.g., ASK, COMPARE, FCET2EC, POLAR, and SUPERB), including training more
providers than were required (e.g., FCET2EC and VERSE) and allowing additional time to
stagger recruitment of participants, training, and/or completion of intervention (e.g., Big
CACTUS, COMPARE, SUPERB, and VERSE).

Strategies to address training providers
Training providers refers to the training of treatment providers to ensure that they can
adequately and consistently deliver the intervention. Standardisation of training is
a strategy described in all seven trials and includes the use of the same and/or certified
trainers, set training materials, and/or a clear description of the length of training. An
example of extended practice was having the training sessions videotaped and indepen
dently rated against a fidelity checklist (e.g., SUPERB).
To demonstrate that researchers ensured or monitored the acquisition of skills by
providers and accommodated for differences between them, provider training included
opportunities for discussion and questions. Specific strategies included video recording to
ascertain a provider’s understanding of the training content followed by monitoring of
therapy sessions, which were also recorded (e.g., COMPARE), review of video recording for
each provider’s first intervention sessions (e.g., ASK) or a selection of treatment sessions
(e.g., VERSE), feedback given after a session delivered in the first week of treatment (e.g.,
POLAR), independent rating of videotaped training sessions for skill acquisition (e.g.,
SUPERB), or a quiz to evaluate the knowledge of providers (e.g., Big CACTUS).
To minimise provider/therapist drift, a range of strategies was used, including regular,
scheduled supervision (e.g., FCET2EC, POLAR, and SUPERB) or refresher supervision and
training as necessary (e.g., ASK, COMPARE, and VERSE). To monitor drift, strategies
included monitoring written therapy documentation, which underwent quality assurance
checks and at least weekly telephone conversations with providers (e.g., FCET2EC), or
giving providers a quiz at 5, 10, and 15 months post-training to check provider knowledge
and what they had understood, internalised, and were applying during the trial (e.g., Big
CACTUS). Further examples involved a review of videotaped intervention sessions to give
feedback to providers to ensure skill acquisition (e.g., ASK, COMPARE, POLAR, SUPERB, and
VERSE) and regular site visits (e.g., VERSE).
To accommodate for provider differences, training was given to all providers regardless
of existing qualifications and/or experience levels (e.g., Big CACTUS, COMPARE, FCET2EC,
and VERSE). Small group training was reported to ensure the individual needs of provi
ders, who were people with aphasia, were met (e.g., SUPERB). In addition,
a predetermined clinically acceptable level of protocol adherence for treatment sessions
was reported to ensure all providers were consistent in their delivery (e.g., ASK, COMPARE,
VERSE, and FCET2EC).

Strategies to address delivery of treatment
Delivery of treatment refers to strategies that determine if the intervention is delivered as
intended. To control for provider differences, how the treatment was delivered by
individual providers was monitored in different ways, including daily therapy logs or
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visit records (e.g., COMPARE, SUPERB, ASK, FCET2EC, and VERSE), documentation of
therapy choice (e.g., Big CACTUS), standardisation of training for key therapeutic elements
such as the rate of presentation of materials and therapeutic techniques (e.g., COMPARE,
POLAR, and FCET2EC), and recording adverse events, complaints, and/or problems
reported (e.g., COMPARE, FCET2EC, SUPERB, VERSE, and ASK). Ratings of session adher
ence help to control for differences between treatment providers (e.g., ASK, COMPARE,
POLAR, SUPERB, and VERSE). In SUPERB, where the providers of the peer-befriending
intervention were people with aphasia, criteria for matching a provider with a participant
were monitored and recorded. Examples of extended practice included qualitative inter
views for a selection of participants at the end of the trial to assess provider perceptions
and experiences of the intervention (e.g., SUPERB, VERSE, and ASK) or completion of
a questionnaire by providers to describe differences in the therapeutic bond, and goal
and task agreement (e.g., Big CACTUS).
To reduce differences within treatment, strategies included training on key therapeutic
elements (e.g., COMPARE and VERSE), self or independent ratings of session adherence
(e.g., ASK, COMPARE, POLAR, SUPERB, VERSE), supervision and feedback to providers (e.g.,
ASK, COMPARE, FCET2EC, POLAR, SUPERB, and VERSE), use of a standardised treatment
manual (e.g., Big CACTUS, FCET2EC, SUPERB, and VERSE), and use of a scripted and
continuously monitored intervention protocol (e.g., FCET2EC).
To ensure and monitor adherence to protocols, intervention sessions were monitored
using videotaped sessions rated against fidelity checklists that contained key criteria (e.g.,
ASK, COMPARE, SUPERB, and VERSE) or using a combination of face-to-face and video
taped sessions (e.g., POLAR). These ratings were completed by an independent assessor in
some studies (e.g., SUPERB, VERSE, and COMPARE). The proportion of face-to-face or
videotaped intervention sessions rated overall ranged from 10% to 25% (e.g., ASK,
COMPARE, POLAR, SUPERB, and VERSE) with two trials intending to rate all first treatment
sessions (e.g., ASK and COMPARE). Information about the intervention dose was also
recorded and monitored, including the number and length of intervention sessions with
protocol deviations (e.g., ASK, COMPARE, FCET2EC, SUPERB, and VERSE); daily therapy logs
or visit records (e.g., COMPARE, FCET2EC, SUPERB, VERSE, and ASK); and monitoring of
information recorded by therapy software (e.g., Big CACTUS). In some trials, feedback was
given to the providers about adherence during the course of the trial (e.g., ASK, COMPARE,
FCET2EC, SUPERB, and VERSE).
A range of strategies were employed to minimise contamination between conditions.
Providers were trained to not liaise with providers of other conditions (e.g., VERSE) and to
give a single intervention (e.g., ASK and SUPERB). Each healthcare/community location was
responsible for a specific intervention condition (e.g., COMPARE and ASK); study partici
pants in the control arm were not explicitly aware of the intervention tested (e.g., SUPERB
and ASK). In two trials, contamination was not expected as no treatment was given by the
provider during the waiting period (e.g., FCET2EC) or was limited due to the requirements
of the computer software used in the treatment (e.g., Big CACTUS). Extended practice
included monitoring of all trial conditions to determine what intervention they received
(e.g., Big CACTUS, COMPARE, FCET2EC, and SUPERB). In one trial, a planned review of
videotaped sessions from all conditions to monitor the risk of contamination was planned
but partially achieved (e.g., VERSE). Should contamination be found, a protocol deviation
would be logged and provider retraining commenced (e.g., COMPARE).
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Strategies to address treatment receipt
Treatment receipt assesses whether the participant can comprehend the intervention
and use the skills being taught. Strategies in this area included more subtle methods,
such as training the providers or having professionals (i.e., speech and language
therapists) who already have skills in supporting communication to deliver the inter
vention (e.g., ASK, Big CACTUS, FCET2EC, POLAR, SUPERB, and VERSE) or specifying
minimum comprehension or cognitive ability as a study inclusion criterion to ensure
sufficient skills to take part (e.g., Big CACTUS, FCET2EC, and VERSE). The design of
some interventions included incremental (or adaptive) levels or a stage structure
whereby a participant needed to comprehend the intervention and use the cognitive
skills being taught to be able to progress (e.g., Big CACTUS, COMPARE, FCET2EC, and
VERSE). An example of extended practice was the review of videotaped intervention
visits or treatment logs to monitor the degree with which a provider ensured
a participant’s comprehension and had sufficient cognitive skills to carry out and
benefit from the intervention (e.g., POLAR and SUPERB). In addition, providers
reviewed completed homework exercises and monitored participant performance
daily to ensure the participants had understood training instructions (e.g., FCET2EC).
To ensure a participant could perform the behavioural skills being taught, a range of
strategies were used, including goal achievement (e.g., VERSE), functional communication
ability measured by video recorded conversations (e.g., Big CACTUS), performance in group
therapy sessions as monitored by therapy supervisors (e.g., FCET2EC), and an activity log
that demonstrated the use of therapy skills completed between sessions (e.g., COMPARE).

Strategies to address treatment enactment
Treatment enactment evaluates whether the participant demonstrates the ability to “use the
intervention” in real-life settings. “Using the intervention” means employing the cognitive
and behavioural skills that were taught during the intervention. Compared to other fidelity
areas, treatment enactment may be harder to capture and has received less attention in
aphasia RCTs. Examples of strategies to use here include qualitative interviews of a purposive
sample of participants to explore their experiences and the impact of the intervention on
their performance (e.g., Big CACTUS and SUPERB), examining the extent with which the
language learned was then used in everyday conversation with volunteers (e.g., Big CACTUS)
or the use of self-reported outcomes or behavioural measures that probed the participants’
use of the taught skills (e.g., simulated everyday life communication scenarios such as roleplays in FCET2EC and functional communication measures in COMPARE).

Recommendations
Having reviewed the literature on fidelity standards (Bellg et al., 2004; Borelli et al., 2005;
Borrelli, 2011; Carroll et al., 2007) and fidelity strategies employed in a sample of ongoing
and recently completed aphasia RCTs, we propose a set of recommendations for aphasia
researchers to appropriately address fidelity when planning, conducting, and reporting
aphasia intervention trials.
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● Fidelity monitoring should be seen as an integral part of all intervention trials

(whether explanatory or pragmatic).
● Intervention trials should have a fidelity monitoring plan/protocol at the outset of

the trial (Feely et al., 2018).
● Explanatory trials need to ensure fidelity; pragmatic trials need to monitor fidelity and

●

●

●

●

●
●

statistically control for any effects of variable fidelity. Depending on the phase of
a trial and the question of interest, some areas of fidelity need to be addressed to
a greater or lesser extent. For example, treatment enactment may be a lower priority
in early feasibility trials that do not evaluate efficacy and effectiveness.
Study design: The intervention dose within and between all trial arms should be
ensured/monitored including the control group. Active ingredients or essential
components of the intervention should be clearly defined, described, and operatio
nalised in a fidelity checklist (or list of protocol behaviours to be observed).
Fidelity checklists should be created systematically, including developing an inter
vention framework, obtaining stakeholder feedback, and piloting the checklist to
improve inter-rater reliability (Walton et al., 2020).
Training providers: a detailed description is required regarding how providers are
trained before the commencement of intervention. Providers should be clear about
the active ingredients of the intervention (e.g., fidelity checklists should be shared
with providers). Supervision and feedback to providers during the intervention
should be specified to monitor adherence to the protocol.
Delivery of treatment: adherence to intervention should be ensured or monitored using
a range of data collection strategies including written data (e.g., daily records and
activity logs) and/or observation of sessions (e.g., videorecorded sessions). Sessions
should be rated for adherence. Researchers should aim to rate adherence for a high
proportion of sessions, as feasible within their trial design. Rating 20% of sessions is
considered optimal (Borrelli, 2011); when this is not feasible, we would recommend
rating a minimum of 10% of sessions. A predetermined acceptable level of session
adherence should be set (e.g., 100% of a specific set of behaviours; 80% of the general
target behaviours). Failure to reach an acceptable level should be recorded as a protocol
deviation and a management plan to mitigate future instances should be described.
Treatment receipt: participants’ grasp of the information provided and ability to apply
the trained behaviours should be assessed.
Treatment enactment: participants’ application of the behaviours/skills to real-life
settings should be assessed. Assessment methods may include questionnaires, selfreports, follow-up interviews, and telephone calls (Bellg et al., 2004; Borrelli, 2011) as
well as conversation samples or assessment of target performances in nontherapeutic environments.

Discussion
The aim of this paper was to describe how fidelity has been addressed across recent
aphasia RCTs and to develop core recommendations for fidelity in aphasia intervention
trials. Historically, fidelity monitoring was not consistently embedded within aphasia
intervention studies. Previous reviews of fidelity monitoring in aphasia intervention
studies have found that less than half explicitly assessed adherence via video recordings
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of intervention sessions (Hinckley & Douglas, 2013), less than a quarter reported super
vision of the intervention (Hinckley & Douglas, 2013) and in aphasia RCTs published prior
to 2017 only around 50% reported on training providers and delivery of treatment
(Brogan et al., 2019). The current paper demonstrates a shift in the field of aphasiology
towards more consistent and comprehensive fidelity monitoring and reporting. Seven
aphasia RCTs were reviewed, including trials of different phases (phases II to IV) and both
explanatory and pragmatic trials. Encouragingly, four trials at least partially met all five
areas of fidelity, with the remaining three trials at least partially meeting four areas. Such
a finding indicates that fidelity is increasingly being considered in the planning and
reporting of aphasia intervention trials. Furthermore, the interpretation of fidelity in
aphasia RCTs has moved beyond treatment adherence, indicating progress from the
historic focus of fidelity in stroke rehabilitation research (Walker et al., 2017). Based on
the literature and the reviewed RCTs, we provided a detailed but not exhaustive descrip
tion of potential fidelity strategies to use and developed initial recommendations to help
guide researchers as to what areas of treatment fidelity to consider for a range of trial
phases.
Pragmatic trials present a challenge to the Bellg et al. (2004) framework as they monitor
rather than ensure fidelity. In such trials, firstly, any modifications to the intervention
should be systematically documented, using, e.g., FRAME (Stirman et al., 2019), to under
stand their impact. Secondly, alternative frameworks of fidelity may also be appropriate
such as that proposed by Carroll et al. (2007), which focuses on treatment adherence (i.e.,
content and dose) and the factors that may influence the degree with which the inter
vention is implemented in practice (i.e., comprehensiveness of policy description, strate
gies to facilitate implementation, quality of delivery, and participant responsiveness).
However, the Carroll et al. framework appears to place less emphasis on the receipt and
enactment of the treatment and conceptualises these areas as more related to participant
responsiveness. To guide researchers in such instances, the fidelity strategies employed
by two pragmatic trials included in this paper, i.e., FCET2EC and Big CACTUS, may be
helpful.
Treatment receipt and enactment have been addressed in less than 12% of aphasia
intervention trials (Brogan et al., 2019). All seven trials reviewed here at least partially
reported on an element of treatment receipt and four reported on an element of
treatment enactment. Both these areas of fidelity extend the focus beyond the provider
to the participant, underlining that an intervention should not merely be provided, but
also received and consecutively lead to a change in everyday life. These areas partially
overlap with the assessment of treatment effectiveness, which is likely assessed beyond
a trial’s fidelity plan. The fidelity domain of enactment continues to present challenges
for definition, assessment, and reporting. Enactment may be difficult to assess because
of the complex nature of communication (not a single behaviour to observe), the
heterogeneity of aphasia, and because of limited or absent carer support to facilitate
the use of taught skills in the home and community settings. Expert consensus is
needed to determine whether other assessments completed during a trial (e.g., activity
logs, conversation samples, and talk time) may be suitable strategies to measure
enactment.
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A challenge within this paper related to achieving agreement between raters in
whether a requirement was met, partially met, or not met; with reliability coefficients
ranging from fair to very good. A large proportion of disagreement related to whether
a requirement was met or partially met. One difficulty may lie in the strategies proposed
by Borelli et al. (2005) and Borrelli (2011), which were designed for health behaviour
change trials where one specific behaviour is targeted (e.g., smoking). In aphasia,
typically a range of behaviours are addressed as part of the intervention. However,
there was also inconsistency in the raters’ interpretation of the criteria and strategies.
Pilot rating of a study with discussion between assessors on criteria and rating discre
pancies may help ensure a common understanding of criteria and higher agreement in
the future.
Moreover, the recommendations proposed in the current paper were generated
through discussion and consensus agreement within a group of experienced aphasia
trialists interested in treatment fidelity. A systematic methodology such as an e-Delphi
exercise may be considered in future research in this area to determine the most
important aspects of fidelity assessment in aphasia rehabilitation. The focus of this
paper has been on treatment fidelity, which is only one aspect of fidelity. Researchers
may also want to consider fidelity of assessment, which has been reported for two of the
trials comprised in the current paper (i.e., COMPARE, POLAR).

Conclusions
This paper describes how the field of aphasiology has progressed in its monitoring and
reporting of treatment fidelity. Referring to a selection of ongoing or completed aphasia
trials as exemplars, we highlight examples of fidelity strategies that represent good
practice to guide planning of future stroke and aphasia intervention trials. Treatment
fidelity should be considered as integral to trial designs in the evaluation of interventions.
A range of strategies should be selected depending on the phase and design of the trial.
Enhanced fidelity monitoring and reporting will support transparency of trial reporting,
increase our confidence in the trial results, and ultimately improve clinical decisionmaking for the benefit of people living with aphasia.
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Trial design
Parallel group: where participants are randomised to one of two or more treatments, which are
compared
Crossover: main alternative design to the parallel group designs where all participants receive the
same treatment(s), but the order in which they receive them depends on the arm to which they are
randomly assigned.
Superiority: trials designed to detect the superiority of a treatment compared to other treatment(s), in
contrast to trials that are designed to assess non-inferiority or equivalence.

Blinding/masking (safeguard strategy against bias)
Open label: where researchers, providers, and participants are all aware of the treatment assigned
because blinding to treatment assignment is difficult or impossible. Frequently applied in combina
tion with blinded endpoint evaluation (see below).
Single-blind: where either the researcher collecting data, the healthcare provider, or the participant
is blind to the treatment assigned.
Double-blind: where both the researcher collecting the data and the participant are blind to the
treatment assigned.
Blinded endpoint: An independent investigator or preferably an endpoint committee who was
blinded to the group assignment (and preferably time of assessment in designs involving a baseline
assessment) did the assessment of clinical recovery in the study (blind end point assessment).
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